Skip to content
    Guidelines & Consensus

    Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin

    Velasco et alSupportive Care in Cancer

    Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin
    Brentuximab vedotin (BV) provides a therapeutic advancement in treating CD30-positive lymphomas, but its clinical utility is frequently constrained by BV-induced peripheral neuropathy (PN). Due to a scarcity of evidence-based, BV-specific guidelines, clinical practice patterns vary widely. To address this, an international modified Delphi panel was conducted to generate consensus recommendations on optimal assessment, monitoring, and management strategies.
    The panel included 13 multidisciplinary experts from eight countries across haematology, neurology, dermatology, nursing, and allied health disciplines. Following three rounds of structured surveys derived from a targeted literature review and expert steering committee input, consensus (defined as ≥ 70% agreement or disagreement) was achieved on 60 of 87 statements (69%).
    Agreed-upon recommendations emphasize routine risk factor profiling prior to initiating BV, implementing validated assessment tools at baseline and throughout therapy, fostering multidisciplinary collaboration, and intervening early when PN worsens. In contrast, the panel identified persistent clinical uncertainty and practice variability regarding the management of intermediate-grade PN and optimal non-pharmacological approaches. The authors emphasize the need for early identification, personalised care, and further research to inform future clinical practice guidelines.

    Key Takeaways

    • An international modified Delphi panel reached consensus on 60 of 87 statements (69%) regarding the assessment, monitoring, and pharmaceutical and non-pharmaceutical management of brentuximab vedotin-induced peripheral neuropathy.
    • Expert recommendations advise routine risk profiling prior to brentuximab vedotin initiation, continuous monitoring with validated assessment tools starting at baseline, multidisciplinary collaboration, and prompt intervention when neuropathy worsens.
    • Practice variability and clinical uncertainty persist regarding the management of intermediate-grade peripheral neuropathy as well as the identification of optimal non-pharmacological interventions.
    Read the original sourceSupportive Care in Cancer